Apellis Pharmaceuticals Inc (NASDAQ:APLS) Could Improve Your Long Portfolio After Less Shorts Reported

September 16, 2018 - By Palma Niemeyer

The stock of Apellis Pharmaceuticals Inc (NASDAQ:APLS) registered a decrease of 31.5% in short interest. APLS’s total short interest was 1.92M shares in September as published by FINRA. Its down 31.5% from 2.80M shares, reported previously. With 204,300 shares average volume, it will take short sellers 9 days to cover their APLS’s short positions. The short interest to Apellis Pharmaceuticals Inc’s float is 8.21%.

The stock decreased 1.59% or $0.3 during the last trading session, reaching $18.51. About 207,341 shares traded. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has 0.00% since September 16, 2017 and is . It has underperformed by 15.62% the S&P500.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company has market cap of $1.04 billion. The Company’s lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. It currently has negative earnings. The firm develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration.

More news for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) were recently published by: Nasdaq.com, which released: “Apellis Pharmaceuticals Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With …” on September 12, 2018. Nasdaq.com‘s article titled: “Apellis Pharmaceuticals Announces that All Four Severely Anemic Solirisâ„¢-Treated Patients with Paroxysmal …” and published on September 04, 2018 is yet another important article.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.